The delivery technique relies on LNP (lipid nano particles) which is fairly refined and existing therapeutics use today. There are potential patent violations though (both Phizer and Moderna possibly violating Arbutus patent) but itβs unclear to me how this affects distribution.
No judge in their right mind will grant an injunction when doing so will cost the lives of third parties. All the harms can be solved with a big check.
Yeah I'm not 100% familiar with the potential case here but I'd imagine it's in everyone's best interest to ensure that the medicine is not hindered in its ability to be manufactured and delivered and that the company that holds patents on the delivery vehicle (LNP) would be compensated justly.
It isn't a new thing for what it's worth. Going back to earlier this year it has been looked at, but we don't really have a clear picture on what will shake out.
